Particle.news

Hone Health Raises $228 Million to Scale AI‑Powered Longevity Platform

A celebrity‑led $28 million equity extension plus a $200 million revenue‑repayable growth facility will finance AI, expanded diagnostics, Longevity OS expansion, clinical trials, commercialization.

Overview

  • Hone disclosed the $228 million financing on Wednesday, Nov. 18, 2026, made up of a $28 million equity extension led by Jay‑Z’s MarcyPen and $200 million from General Catalyst’s Customer Value Fund.
  • The company says the $28 million equity will be used to build AI tools that let a single physician manage issues across specialties and to expand its Longevity OS and diagnostics.
  • General Catalyst’s $200 million is structured as growth capital that pays for sales and marketing and is repaid from revenue with no recourse or loan covenants, which Hone intends to use to accelerate customer acquisition.
  • Hone is publicly launching Hone Black after a stealth period; the concierge membership pairs testing of more than 1,600 health markers with a dedicated physician team and may include peptides and exosome offerings that face existing FDA warnings and legal scrutiny.
  • The financing leans on Hone’s scale—company‑reported recurring revenue above $100 million and roughly 200,000 patients treated—and supports founder Saad Alam’s Time Therapeutics plan to run remote clinical trials and commercialize therapies, while regulatory risk could limit how quickly high‑touch treatments roll out.